Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07419373Phase 2Recruiting

ARN-75039 Lassa Fever Treatment in West Africa

Role: collaborator

NCT06212336Phase 2Recruiting

ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Role: lead

NCT03655561Active Not Recruiting

Lassa Fever Clinical Course and Prognostic Factors in Nigeria

Role: collaborator

NCT04907682Phase 2Completed

Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever

Role: collaborator

All 4 trials loaded